Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06950892 · ClinicalTrials.gov registry record

Remote Sputum Collection in Cystic Fibrosis

A clinical trial of Cystic Fibrosis and Infections, sponsored by University of Pennsylvania.

Recruiting
Registry status
150
Enrollment target
3
Study locations

NCT06950892: Recruiting study of Cystic Fibrosis and Infections, sponsored by University of Pennsylvania.

NCT06950892 is a study of Cystic Fibrosis and Infections that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 150 participants, below the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (16% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06950892, a study of Cystic Fibrosis and Infections, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
150 participants
Enrollment target
3
Study locations

Study Summary

Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collecting sputum samples at home and sending them by mail may be feasible, uncertainty remains about how the collection of samples outside of clinic and delays in testing while in the mail impact infection detection. This study will compare bacterial cultures using sputum samples collected at home versus samples collected in clinic (saline-induced sputum and throat swab). This study seeks to shed light on how valuable home collected samples can be and help us better understand the usefulness of home-collected sputum samples for both clinical and research purposes.

Study Locations (3)

Colorado

  • National Jewish Health - Denver

Maryland

  • Johns Hopkins University - Baltimore

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-01-15
Est. Completion 2028-06-30
University of Pennsylvania

1,423 total trials

What NCT06950892 shows while recruiting

NCT06950892 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (16% lower).

The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.

NCT06950892 reports a single indexed study location in Colorado, Maryland, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06950892 about?

NCT06950892 is a clinical study titled "Remote Sputum Collection in Cystic Fibrosis". Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collecting...

What is the current status of trial NCT06950892?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-01-15. Estimated completion is 2028-06-30.

What conditions does trial NCT06950892 study?

This clinical trial studies the following conditions: Cystic Fibrosis, Infections.

Who is sponsoring clinical trial NCT06950892?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06950892 being conducted?

This trial has 3 study locations across Colorado, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06950892's enrollment target sits among peer trials

150 43rd of 169 higher than 125 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06950892, the US trial registry maintained by the National Library of Medicine. NCT06950892 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.